DUBLIN, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of three abstracts for presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Poster presentations will occur Nov 7 – 9 in Dublin, Ireland.
| XIAP | Abstract #85, Poster Board #052 | ||
| Poster Presentation: | Wednesday, Nov 7, 2012 | 12:00 – 2:15 pm GMT | |
| Characterization of a potent XIAP and cIAP1 dual antagonist in models of melanoma and leukemia | |||
| AT13387 | Abstract #293, Poster Board #043 | ||
| Poster Presentation: | Thursday, Nov 8, 2012 | 12:00 – 2:15 pm GMT | |
| Activity of the HSP90 inhibitor, AT13387, in ALK-driven tumor models | |||
| SGI-110 | Abstract #465, Poster Board #036 | ||
| Poster Presentation | Friday, Nov 9, 2012 | 8:30 – 10:30 am GMT | |
| SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib activity and alters methylation signature of HCC cell lines | |||
Select posters will be made available for viewing on the company's website http://astx.com/pipeline/publications/ following the public presentation.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273